ArticleBMC psychiatry2025
Cortical morphometric inverse divergence alterations in first-episode, treatment-naïve COVID-19 secondary depression correlate with transcriptional signatures.
Article in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Epicenter mapping of cortical morphological dedifferentiation in type 2 diabetes mellitus using morphometric inverse divergence.Frontiers in aging neuroscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTheneurobiological mechanisms underlying COVID-19 secondary depression(CSD) remain poorly understood, particularly regardingmacrostructural brain alterations and their transcriptionalcorrelations. This study aimed to investigate regional morphometricinverse divergence (MIND) alterations and their molecularassociations with cortical transcriptional signatures in CSDpatients.
methods80 first-episode, treatment-naïve CSD patients and 40 matched healthycontrols underwent high-resolution structural MRI. MIND networks wereconstructed across 308 cortical regions using five morphometricfeatures. Case-control differences were assessed using general linearmodels adjusting for age, sex, and intracranial volume. Partial leastsquares (PLS) regression was employed to link regional MINDalterations with cortical gene expression profiles, meta-analyticcognitive domains, and transcriptomic features includingcross-disorder similarity, functional pathways, cell-typespecificity, cortical layer distribution, and developmental timing.
resultsCSDpatients exhibited significantly elevated MIND values in cingulateand supramarginal regions associated with emotional, memory, andlanguage processing. These changes correlated with stress andcognitive symptoms, independent of infection frequency. PLS4-weightedgenes explained 17.7% of MIND variance and were enriched inneurodevelopmental and metabolic (PLS4+), as well as immune-related(PLS4-) pathways. PLS4- genes were linked to microglia, astrocytes,and cortical layer-I, while PLS4+ genes localized to layer-V.Developmental enrichment indicated disruptions during early (fetal,infant) and late (adult) stages.
conclusionsThis study reveals that regional MIND alterations in CSD are underpinned by distinct transcriptional signatures, highlighting neurodevelopmental and immune-related mechanisms. These findings offer a multiscale framework connecting brain morphometry with transcriptional architecture in post-COVID depression. CLINICAL TRIALS: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.